Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
about
The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-AnalysisHow to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancerGenomic profiling in luminal breast cancerBiomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerDistinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcomeSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Towards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyLZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors.MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesisPrecision medicine in breast cancer: reality or utopia?PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).Biological subtypes of breast cancer: Prognostic and therapeutic implications.GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2).Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerGeographic differences in the distribution of molecular subtypes of breast cancer in BrazilTumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.Age-specific changes in intrinsic breast cancer subtypes: a focus on older womenPAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges.Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigaLocal recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune contextReports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trialsAddressing overdiagnosis and overtreatment in cancer: a prescription for changeGene co-expression modules as clinically relevant hallmarks of breast cancer diversity.Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.Evaluating many treatments and biomarkers in oncology: a new designAdvances in Statistical Approaches Oncology Drug Development.Elevation of SIPL1 (SHARPIN) Increases Breast Cancer RiskSerial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response.Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.
P2860
Q26765032-4EB45CB9-B3A0-410F-8C5F-AB8C194868FDQ26798419-21C29D4C-7C17-4097-A2FE-1E7273D2A031Q26862681-837D7C8F-06AE-4D40-AF04-57D0DA6C4B42Q27010096-7029BB56-0489-4AE2-AA32-1BFB3AF71829Q27025863-544F12C4-1E59-41DE-A68B-1B585988D6C2Q28273187-436B9DBB-1E88-44E2-9BBA-3653928838FAQ30240816-FA774BFC-F7E7-4894-A6FF-428A3E70DD5EQ30435832-474E4AB3-5A5C-4904-843E-029AD8D7BDAAQ33572016-DC2D7AEA-283C-4465-B612-FC1A8059B3C9Q33572318-CFE1CDA4-5FAD-46C0-BD4B-126D37BCFA05Q33632205-74B3FC2C-54C3-4762-A445-D15382654C21Q33671140-AC81EAA0-568A-4589-B966-8A8FF9ED72C0Q33762222-579132B0-DBAB-4B3D-B4FE-21FB5BB817ECQ33779406-6CE35EFE-1E5F-403E-A917-B49D83FBA15BQ33809114-1591B480-9872-4C0B-8FD8-0DC2D5FD8382Q33883406-295939E9-3704-42AF-AFB1-AF734B56F1DAQ33913615-32CF6AC5-7F59-4A64-8ABA-7CBBCB8DD55AQ34023695-04E89DDF-FABC-412C-B069-3BFCF1B69970Q34107170-CB4607FD-9661-4442-953C-EA2566EB48E5Q34120668-4E62678E-F97F-48D8-B751-F997D1462A0BQ34125691-6DA79419-C0E4-499F-8A6A-D68A26052B29Q34158197-7DA55D66-E50D-48D0-BCC7-0EEDCBF80EC6Q34359310-955AFF2A-0B12-41D1-81E9-7FC3043B7B3AQ34433549-DA710215-528C-4FC6-8042-4EF510427757Q34503415-6A895517-0A63-4F45-BCCE-9C0216B1D97BQ34670535-328747E2-A103-4B4D-9F5B-78516C5BBA96Q34880376-735995FA-07CF-454D-B6CB-A6C892EDCEFEQ34956588-5F63D2AF-176E-45FA-A9CF-E92710DB4A36Q35000874-3D18CB8F-05FA-40B1-AF16-73EDF2FE528DQ35036920-0E7C8671-F1E4-425F-8D2E-EE18AD9D03FDQ35041013-FBF5C7EE-CE89-429A-96CE-7176514F1A12Q35067706-8910344E-916F-4B7B-A8B0-2F4502582188Q35091690-DB3A4455-31C5-439B-851D-CAD507CFA5D3Q35251049-FFE2ADEB-D8CF-4395-AE29-4EB0F7DE5276Q35379179-DEC9524A-6ADD-43D2-AE06-0AB2CF3C584DQ35565672-9A5E3F0E-30C4-481F-984C-1974CA3C21DAQ35625533-F4A66FFD-01F3-49F5-8AA0-A5F11B6B6567Q35775570-BB14BCCF-2B96-4981-BFBB-24071EC1BE22Q35804283-CC6506E8-FF83-4333-AF52-50E8A1CAA6C4Q35836089-AA9E2568-5AD0-4F31-B71C-DEB3EA20B36E
P2860
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@ast
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@en
type
label
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@ast
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@en
prefLabel
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@ast
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@en
P2093
P2860
P50
P1476
Chemotherapy response and recu ...... GB 150007/150012; ACRIN 6657).
@en
P2093
Angela DeMichele
Baljit Singh
Carolyn Mies
Chad Livasy
Christina Yau
Clifford Hudis
Constance Lehman
David Chhieng
Debu Tripathy
P2860
P2888
P304
P356
10.1007/S10549-011-1895-2
P407
P577
2011-12-25T00:00:00Z